证券代码：300254 证券简称：仟源医药 公告编号：2025-047 山西仟源医药集团股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形； 2.本次股东会未涉及变更以往股东会决议的情形。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议召开时间为：2025年8月7日（星期四）下午2:00 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体 时间为 2025 年 8 月 7 日 9:15-9：25，9：30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为 2025 年 8 月 7 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：上海市徐汇区龙耀路175号星扬西岸3605室 6、会议出席情况： （1）股东出席的总体情况： 通过现场和网络投票的股东 164 人，代表股份 30,010,247 股，占公司有表 决权股份总数的 12.0854％。 3、会议方式：本次股东会采取现 ...

国浩律师（上海）事务所 关于 山西仟源医药集团股份有限公司 2025 年第三次临时股东会 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5234 1670 网址/Website: http://www.grandall.com.cn 二〇二五年八月 作为具有从事中国法律业务资格的律师事务所，国浩律师（上海）事务所（以 下简称"本所"）接受山西仟源医药集团股份有限公司（以下简称"公司"）的委托， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）等法律法规及规范性文件的规定，指派本所 律师出席公司2025年第三次临时股东会（以下简称"本次股东会"），并就本次股 东会的召集、召开程序及表决程序、表决结果等事项出具本法律意见书。 国浩律师（上海）事务所 法律意见书 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-048 山西仟源医药集团股份有限公司 关于 2025 年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 2025 年 7 月 21 日，山西仟源医药集团股份有限公司（以下简称"公司"）召开第 五届董事会第三十次会议，审议通过了《关于<山西仟源医药集团股份有限公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等议案，并于 2025 年 7 月 23 日在 巨潮资讯网（http://www.cninfo.com.cn）披露了相关公告。 1、核查对象为本激励计划的内幕信息知情人 2、本次激励计划的内幕信息知情人均填报了《内幕信息知情人登记表》 3、公司向中国证券登记结算有限责任公司深圳分公司就内幕信息知情人在激励计 划首次公开披露前六个月，即 2025 年 1 月 23 日至 2025 年 7 月 22 日（以下简称"自查 期间"）买卖公司股票情况进行了查询确认，并由中国证券登记结算有限责任公司深圳 分公司出具了《信息披露义务人持 ...

Group 1 - The company Jiangsu Jiayi Pharmaceutical's recently approved drug Ebastine is indicated for the treatment of allergic rhinitis and urticaria [2] - Ebastine tablets are effective in alleviating symptoms of allergic rhinitis, including nasal itching, sneezing, runny nose, and nasal congestion [2]

Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and has publicly disclosed the list of initial grant recipients, following the relevant regulations and guidelines [1][2]. Disclosure and Verification - The initial grant recipient list was publicly announced on July 23, 2025, and was open for feedback for a period of 10 days, during which no objections were received [2]. - The Compensation and Assessment Committee verified the eligibility of the initial grant recipients based on their employment contracts, identification documents, and their positions within the company [2]. Committee's Verification Opinion - The Compensation and Assessment Committee confirmed that all selected recipients meet the qualifications set forth in the relevant regulations and do not fall under any disqualifying conditions [3]. - The recipients do not include independent directors, foreign employees, or shareholders holding more than 5% of the company's shares, ensuring compliance with the incentive plan's objectives [3].

山西仟源医药集团股份有限公司 董事会薪酬与考核委员会关于 2025 年限制性股票激励计划 首次授予激励对象名单的公示情况说明及核查意见 一、公示情况及核查情况 3、公司薪酬与考核委员会对拟激励对象的核查情况 公司薪酬与考核委员会核查了本次激励计划的首次授予激励对象名单、拟激 励对象与公司签订的劳动合同或聘用合同、身份证件、激励对象在公司（含子公 司）担任的职务及其任职文件等资料。 二、薪酬与考核委员会核查意见 根据《管理办法》、《上市规则》、《自律监管指南》等有关规定，以及公 司对本次激励计划的首次授予激励对象名单的公示情况及核查结果，薪酬与考核 委员会发表核查意见如下： 1、列入公司本次激励计划首次授予激励对象名单的人员具备《公司法》等 规定的任职资格。 2025 年 7 月 21 日，山西仟源医药集团股份有限公司（以下简称"公司"） 召开第五届董事会第三十次会议，审议通过了《关于 2025 年限制性股票激励计 划（草案）及其摘要的议案》等相关议案。根据《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、《深圳证券交易所创业板股票上市规则》（以 下简称"《上市规则》"）、《深圳证券交易所创业板上市公 ...

Group 1 - The hepatitis concept sector experienced a short-term surge, with Kewah Bio (002022) hitting the daily limit up [1] - Other companies such as Qianyuan Pharmaceutical (300254), Hendi Pharmaceutical (301211), Da'an Gene (002030), Asia-Pacific Pharmaceutical (002370), and Kangzhi Pharmaceutical (300086) also saw significant increases in their stock prices [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has launched a stock incentive plan for 2025, aiming for high profit growth [6] - The core product, a smoking cessation drug, is expected to maintain a high growth rate, with projected revenue growth for 2025-2027 [6] - The company anticipates achieving a net profit of 0.91 billion, 1.35 billion, and 1.75 billion for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 114.7%, 48.6%, and 30.3% [6] Financial Data and Profit Forecast - Total revenue projections are as follows: 971 million for 2025, 1,132 million for 2026, and 1,286 million for 2027, with respective growth rates of 14.7%, 16.5%, and 13.7% [5] - The expected net profit for 2025 is 91 million, with a significant increase from 42 million in 2024, indicating a growth rate of 114.7% [5] - The projected earnings per share (EPS) for 2025 is 0.36 yuan, increasing to 0.54 yuan in 2026 and 0.71 yuan in 2027 [5] Stock Incentive Plan - The stock incentive plan involves granting up to 9.15 million restricted shares, accounting for 3.68% of the company's total share capital, with an initial grant of 7.95 million shares at a price of 5.60 yuan per share [6] - The performance targets for the incentive plan include revenue growth rates of no less than 8.57%, 18.02%, and 27.57% for the years 2025, 2026, and 2027 respectively [6]

Group 1 - The core point of the news is the announcement of a stock incentive plan by QianYuan Pharmaceutical, which aims to grant a total of 9.15 million restricted shares, accounting for 3.68% of the company's total equity [1] - The initial grant consists of 7.95 million shares, with a reserved 1.2 million shares, targeting 171 individuals at a price of 5.60 yuan per share [1] - The incentive plan's performance targets for 2026-2027 include a profit growth rate exceeding 36%, with revenue growth rates set at no less than 8.57%, 18.02%, and 27.57% for the years 2025, 2026, and 2027 respectively [1] Group 2 - The sales of the smoking cessation drug Varenicline are accelerating, with Q1 2025 sales reaching 17.57 million yuan and a market share of 59.5%, particularly strong in urban pharmacies [2] - The company maintains a "buy" rating, projecting net profits of 91 million, 135 million, and 175 million yuan for 2025-2027, with year-on-year growth rates of 114.7%, 48.6%, and 30.3% respectively [2] - The corresponding price-to-earnings ratios (PE) for these years are projected to be 31, 21, and 16 times [2]

Core Points - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. has successfully achieved the conditions for the first unlock period of its 2024 Restricted Stock Incentive Plan [1][5] - The first unlock period allows for the release of 40% of the granted restricted stocks, which were awarded on June 3, 2024, and the unlock date is set for July 25, 2025 [5][6] - The company has completed the necessary approval procedures and has publicly disclosed the list of incentive objects [2][3] Summary by Sections Incentive Plan Approval - The board of directors approved the first unlock conditions at the 29th meeting of the fifth board on July 17, 2025 [1] - The plan has undergone all required approval processes, including the authorization from the shareholders' meeting [2] Unlock Conditions Achievement - The company has met all conditions for the first unlock period, including no adverse audit opinions and compliance with performance assessment requirements [5][6] - The performance targets for the first unlock period include achieving a revenue growth rate and a net profit growth rate compared to the previous year [6][7] Specifics of the Unlock - A total of 705,000 shares were granted to 50 incentive objects, with 40% eligible for release during this period [3][5] - The total number of shares eligible for release represents 1.08% of the company's total share capital of 248,318,563 shares [9][10] - The company has also noted that three incentive objects have left the company, resulting in the repurchase and cancellation of 350,000 shares [8][9]